ReviewCurrent urology reports2026
Management of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis.
Review in Current urology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review critically evaluates recent literature from the past five years concerning the management of lower urinary tract symptoms (LUTS) in patients with multiple sclerosis (MS), highlighting advances in understanding disease mechanisms, diagnostic strategies, and therapeutic options. RECENT
findingsLUTS can affect up to 90% of MS patients and arise due to lesions within the brain or spinal cord. Emerging insights emphasize the complexity of symptom presentation and the limitations of symptom-based diagnosis alone, underscoring the importance of systematic evaluation and multidisciplinary approaches. Treatments include patient centered behavioral and pharmacological therapies, minimally invasive options such as botulinum toxin injections or neuromodulation, and surgical management. Effective management of LUTS in MS demands a multidisciplinary, patient-centered approach focused on renal function preservation and quality of life improvement. Future research should address disease-specific guidelines and personalized care strategies.
Indexed as
Identifiers
42249106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.